Background:The non-alcoholic fatty liver disease is increasingly being recognized as a major cause of liver related morbidity and mortality among 15-40% of the general population. The rising incidence of obesity is associated with health complications. Currently, a liver biopsy is the gold standard method for diagnosing NAFLD. Ultrasonography is relatively inexpensive and widely available in clinical settings. NAFLD is considered to be an integral part of the metabolic syndrome. Objective: To find out the clinical profile with non-alcoholic fatty liver disease and metabolic syndrome patients.Methods: A cross-sectional study was conducted by Department of Cardiology, Enam Medical College and Hospital, Savar, Bangladesh. A total of 100 cases during the study period of February 2019 to January 2020 were included and investigated for metabolic syndrome according to the NCEP ATP 3 Criteria. Results: Total of 100 cases ultrasonographically diagnosed as NAFLD were included in the study and showed 49%, 38% and 13% of cases had grade I, II, and III fatty liver respectively. On physical examination mean BMI was 27.6±4.39 kg/m 2. Mean diastolic blood pressure was 92.87±6.25 and mean systolic blood pressure (mm Hg) 132.0±18.17. Out of the 100, patients with NAFLD with metabolic syndrome were 57% and without metabolic syndrome were 43%. The correlation was significant for fasting plasma glucose, diastolic blood pressure, triglycerides, high-density lipoprotein and waist circumference (p<0.05). Conclusions: From the study, it can be concluded that symptoms and signs of NAFLD are non-specific and occur later in the course of the disease hence the physician should have a high index of suspicion in order to detect NAFLD early in the course of the disease. Early detection would help not only in modifying the disease course and delaying its complications.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.